Loading…
Signature Formulations, LLC, a manufacturer of over-the-counter drug products in Phoenix, Arizona, was cited for significant Current Good Manufacturing Practice (CGMP) violations on January 21, 2026, following an FDA inspection in July 2025. The company failed to maintain adequate facility separation and controls to prevent cross-contamination when manufacturing multiple drug products with potent active ingredients in a shared space using shared equipment, including a specific instance where equipment was used to manufacture a potent drug product immediately before manufacturing children's toothpaste. This manufacturing deficiency rendered the company's drug products adulterated and presented significant risk to patient safety, as the firm acknowledged only that contamination control systems were "under study" rather than implementing immediate corrective measures.